Summary
This 8-K filing from Edwards Lifesciences Corporation, dated November 14, 2008, reports a change in its Board of Directors' committee composition. Specifically, Robert A. Ingram has been appointed to the Audit and Public Policy Committee, effective immediately. This appointment fills a vacancy caused by the passing of former committee member Philip M. Neal. For investors, this information primarily relates to corporate governance. The addition of Mr. Ingram to a key committee signifies a continuation of the board's oversight functions following a recent vacancy. While not directly impacting current financial performance, such changes are important for understanding the stability and continuity of the company's governance structure.
Key Highlights
- 1Robert A. Ingram appointed to the Audit and Public Policy Committee.
- 2Appointment is effective immediately as of the November 13, 2008 Board of Directors meeting.
- 3The vacancy on the committee was created by the death of Philip M. Neal.
- 4This filing is an 8-K reporting an 'Other Event' related to board committee changes.
- 5The company is Edwards Lifesciences Corporation (EW).
Frequently Asked Questions
The main purpose of this 8-K filing is to report a change in the composition of Edwards Lifesciences' Board of Directors' Audit and Public Policy Committee.
Robert A. Ingram has been appointed to the committee to fill the vacancy left by the passing of Philip M. Neal.
This filing primarily concerns corporate governance and does not directly report any immediate financial results or material changes to the company's financial standing. However, changes in board committees can be part of a broader assessment of a company's governance.
The appointment of Robert A. Ingram to the committee was effective immediately following the regular meeting of the Board of Directors on November 13, 2008.